Efficacy of different modalities of LHRH agonist (buserelin) administration on the inhibition of the pituitary-ovarian axis for the treatment of endometriosis.
D000281:Administration, Intranasal; D002064:Buserelin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004715:Endometriosis / Q000188:drug therapy* / Q000473:pathology; D004717:Endometrium / Q000473:pathology; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006801:Humans; D007279:Injections, Subcutaneous; D007986:Luteinizing Hormone / Q000378:metabolism; D010053:Ovary / Q000187:drug effects / Q000503:physiopathology*; D010902:Pituitary Gland / Q000187:drug effects / Q000503:physiopathology*
D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin